7485 GI/2018
(1)
jftLVªh laö Mhö ,yö&33004@99
REGD. NO. D. L.-33004/99
vlk/kj.k
EXTRAORDINARY
Hkkx II—[k.M 3—mi&[k.M (ii)
PART II—Section 3—Sub-section (ii)
izkf/dkj ls izdkf'kr
PUBLISHED BY AUTHORITY
la- 5013]
ubZ fnYyh] 'kqØokj] fnlEcj 21] 2018@vxzgk;.k 30] 1940
No. 5013]
NEW DELHI, FRIDAY, DECEMBER 21, 2018/AGRAHAYANA 30, 1940
jlk;u vkSj moZjd ea=ky;
¼vkS"k/k foHkkx½
¼jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k½
vkns’k
ubZ fnYyh] 21 fnlEcj] 2018
dk-vk- 6252¼v½-—vkS"k/k foHkkx }kjk vkS”k/k ¼ewY; fu;a=.k½] 2013 ds iSjk 31 ds varxZr ikfjr
blesa uhps lkj.kh ds LraHk ¼6½ esa fofufnZ”V vkns’kksa ds }kjk tkjh iqufoZyksdu vkns’kksa ds lanHkZ esa fn;s
x, funsZ’kksa ds dk;kZUo;u esa vkSj Hkkjr ljdkj ds jlk;u vkSj moZjd ea=ky; }kjk tkjh dk-vk-
1394¼v½ rkjh[k 30 ebZ] 2013 vkSj dk0 vk0 701¼v½ rkjh[k 10 ekpZ] 2016 ds lkFk ifBr vkS”k/k ¼dher
fu;a=.k½ vkns’k] 2013 ds iSjk 4, 6, 10, 11, 14, 16, 17 vkSj 18 }kjk iznRr ‘kfDr;ksa dk iz;ksx djrs gq,
vkSj lkj.kh ds LraHk ¼7½ esa fofufnZ”V Hkkjr ljdkj ds jlk;u vkSj moZjd ea=ky;] (jk”Vªh; vkS”k/k ewY;
fu/kkZj.k izkf/kdj.k) ds vkns’kksa ds vf/kdze.k esa] tgk¡ rd mldk lEcU/k uhps dh lkj.kh ds fofufeZfr
iSdksa ls gS] mu ckrksa ds flok;] vf/kØkUr djrs gq, ftUgsa ,sls vf/kØe.k ds iwoZ fd;k x;k gS ;k djus
dk yksi fd;k x;k gS] jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k ¼ftldks laf{kIr :i esa ,uihih, dgk
tkrk gS½ uhps dh lkj.kh ds LraHk ¼5½ esa fofufnZ”V vf/kdre dher dks mDr lkj.kh ds LraHk ¼3½ vkSj
¼4½ esa Øe’k% rRLFkkuh izfof”V;ksa esa fofufnZ”V [kqjkd :i ,oa izcyrk vkSj bdkbZ lfgr ml lkj.kh ds
LraHk ¼2½ esa dh rRLFkkuh izfof”V esa fofufnZ”V vuqlwfpr fofufeZfr;ksa esa ls izR;sd ij ykxw oLrq ,oa lsok
dj] ;fn dksbZ gS] dks NksM+dj vf/kdre dher ds :i esa fu;r djrh gS%
lkj.kh
dz-
la-
vuqlwfpr
fofufeZfr dk
uke
[kqjkd :i
,oa izcyrk
bdkbZ
vf/kdre
dher
¼#-½
iqufoZyksdu vkns’k
la- ,oa rkjh[k
ekStwnk dk- vk- la-
,oa rkjh[k
(1)
(2)
(3)
(4)
(5)
(6)
(7)
1.
ikWfoMu vk;ksMhu lksyq'ku 10%
1 fefy-
0.87
31015/24/2018-
ewY; fu/kkZj.k dh
rkjh[k 08.10.2018
1461(v) fnukad
02.04.2018
(at Sl. No. 662)
2
THE GAZETTE OF INDIA : EXTRAORDINARY
[PART II—SEC. 3(ii)]
uksV %
¼d½ ljdkj }kjk bl izdkj fu;r dh xbZ vkSj vf/klwfpr dh xbZ vf/kdre dher ¼/ku oLrq ,oa lsok
dj] tks ykxw gksa½ ls vf/kd dher ij vuqlwfpr fofufeZfr;ksa ds czkaMsM ;k tsusfjd ;k nksuksa :ikarjksa dks
csp jgs vuqlwfpr fofufeZfr;ksa ds lHkh fofuekZrk] mi;qZDr lkj.kh ds LraHk (5) esa of.kZr vf/kdre dher
¼/ku oLrq ,oa lsok dj] tks ykxw gksa½ ls vf/kd lHkh ,slh fofufeZr;ksa dh dher dk v/kkseq[kh la’kks/ku
djsaxsA
¼[k½ mi;qZDr lkj.kh ¼/ku oLrq ,oa lsok dj] tks ykxw gS] ;fn dksbZ gS½ ds LraHk ¼5½ esa fofufnZ”V
vf/kdre ewY; dh vis{kk de [kqnjk ewY; okyh Åij of.kZr vuqlwfpr fofufeZfr;ksa ds lHkh ekStwnk
fofuekZrk Mhihlhvks] 2013 ds iSjk 13¼2½ ds vuqlkj oLrq ,oa lsok dj ds dk;kZUo;u ij mRikn ‘kqYd
vkSj djksa ds varj ds dkj.k vf/kdre [kqnjk ewY; esa gqbZ o`f) ds vykok ekStwnk vf/kdre [kqnjk ewY;
dks fujarj cuk, j[ksaxsA
¼x½ vxj fuekZrkvksa us mi;qZDr lkj.kh ds LraHk (5) esa of.kZr vf/kdre dher ij ljdkj dks okLro esa
Hkqxrku fd;k gS ;k ;g ns; gS rks os oLrq ,oa lsok dj dks tksM+ ldrs gSaA
¼?k½ vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds iSjkxzkQ 11 esa fn, x, izko/kkuksa ds rgr lEcfU/kr
fuekZrkvksa dks mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V vf/kdre dher ds vk/kkj ij vuqlwfpr
fofufeZfr;ksa ds iSdksa ds fy, vf/kdre dher fu/kkZfjr djsaA fuekZrk vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013
ds iSjkxzkQ 24 ds rgr QkWeZ&V esa vf/klwpuk dh rkjh[k ls vkbZihMh,e,l ds ek/;e ls Hkjdj
,uihih, dks ,d ewY; lwph tkjh djsa rFkk mldh dkWih jkT; vkS”kf/k fu;a=dksa vkSj fofuekZrk forjdksa
dks tkjh djsaA
¼M+½ vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds 24 (4) ds mica/kksa ds vuqlkj izR;sd QqVdj fodzsrk vkSj
forjd fofuekZrk }kjk fn, x, :i esa ,sls ifjlj] tgka dkjksckj dks bl izdkj fd;k tk jgk gS fd
mlls ijke’kZ ds bPNqd fdlh O;fDr ds fy, igqap vklku gks] ogka mlds fdlh lgtn`’; Hkkx ij
dher lwph vkSj iwjd lwph] ;fn dksbZ gks] dks laiznf’kZr djsxkA
¼p½ mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V vf/kdre dher ds fy, fofufnZ"V vuqlwfpr fofufeZfr;ksa
ds fofufnZ"V fofHkUu rjhds vkSj izcyrk ls fHkUu vxj ekStwnk fuekZrkvksa }kjk ,d ubZ vkS"kf/k dks ykap
djrk gS rks mls igys vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds iSjkxzkQ 2¼;w½ ds vuqlkj vkS"k/k ¼ewY;
fu;a=.k½ vkns'k] 2013 ds rgr lwph II esa fofufnZ"V QkeZ I ds ek/;e ls ,uihih, esa ewY; fu/kkZj.k gsrq
vkosnu djuk gksxkA
¼N½ mi;qZDr vuqlwfpr fofufeZfr;ksa dh mRiknu@vk;kr vkSj fcØh ds lEcU/k esa fuekZrkvksa dks vkS"k/k
¼ewY; fu;a=.k½ vkns'k] 2013 ds lwph II ds QkWeZ III dks vkbZihMh,e,l ds ek/;e ls Hkjdj ,uihih,
dks gj frekgh dh fjiksVZ izLrqr djsxkA mi;qZDr vuqlwfpr fofufeZfr;ksa ds fuekZ.k dks dksbZ fuekZrk
mRiknu cUn djus dk bPNqd gks rks bldh lwpuk ,uihih, dks voxr djk;sxkA blds lEcU/k esa vxj
vuqlwfpr fofufeZfr;ksa ds mRiknu vkSj vk;kr dks cUn djus dk bPNqd gS rks cUn djus dh frfFk ls N%
eghus igys lwph II ds QkWeZ IV esa Hkjdj ,uihih, dks izLrqr djsxkA
¼Tk½ fofuekZrk ;k foi.ku dEiuh] mijksDr dfFkr lkj.kh esa n'kkZ;s vf/kdre ewY; vkSj 'krks± dk ikyu
ugha djrh gSa rks os vko';d oLrq,¡ vf/kfu;e] 1955 ds lkFk ifBr Mhihlhvks] 2013 ds izko/kkuksa ds
v/khu C;kt lfgr vf/kizHkkfjr jkf'k dks tek djus ds fy, nk;h gksaxsA
¼>½ bl vkns'k esa mijksDr lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V ,slh fofufeZfr;ksa ds
iSdksa dh vf/kdre dher fu;r gksus ds ifj.kkeLo:i] vf/kdre ;k [kqnjk ewY; fu/kkZfjr vkns'k ;fn
dksbZ gks] tks fd bl vkns'k ls iwoZ tkjh gq, gS] Lor% gh vf/kØe.k gks tk,axsA
[dka- la-@193@61@2018@,Q@Qk- la- 8¼61½@2018@Mhih@,uihih,&fMoh-II]
cythr flag] lgk;d funs'kd
¹Hkkx IIµ[k.M 3(ii)º
Hkkjr dk jkti=k % vlk/kj.k
3
MINISTRY OF CHEMICALS AND FERTILIZERS
(Department of Pharmaceuticals)
(NATIONAL PHARMACEUTICAL PRICING AUTHORITY)
ORDER
New Delhi, the 21st December, 2018
S.O. 6252(E).—In implementation of directions given in line with review orders issued by the Department
of Pharmaceuticals (DOP) vide order(s) specified in column (6) of the table herein below passed by the Department
of Pharmaceuticals under para 31 of Drugs (Prices Control) Order, 2013 and in exercise of the powers conferred by
paragraphs 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated
the 30th May, 2013 and S.O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of
Chemicals and Fertilizers, and in supersession of the Order(s) of the Government of India in the Ministry of
Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) specified in the Column (7) of the table
regarding formulation specified in mentioned in the table in so far as it relates to formulation pack mentioned in the
table below, except in respect of things done or omitted to be done before such supersession, the National
Pharmaceutical Pricing Authority, hereby fixes/revises the price as specified in column (5) of the table herein below
as ceiling price exclusive of goods and services tax applicable, if any, in respect of the Scheduled formulation(s)
specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit
specified respectively in the corresponding entries in columns (3) and (4) thereof:
TABLE
Note:
(a) All manufacturers of scheduled formulations, selling the branded or generic or both the versions of
scheduled formulations at a price higher than the ceiling price (plus goods and services tax as applicable)
so fixed and notified by the Government, shall revise the prices of all such formulations downward not
exceeding the ceiling price specified in column (5) in the above table plus goods and services tax as
applicable, if any.
(b) All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the
ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if any,
shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013.
(c) The manufacturers may add goods and services tax only if they have paid actually or if it is payable to the
Government on the ceiling price mentioned in column (5) of the above said table.
(d) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned
manufacturer in accordance with the ceiling price specified in column (5) of the above table as per
provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall
issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA
through IPDMS and submit a copy to State Drug Controller and dealers.
(e) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary
price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries
on business in a manner so as to be easily accessible to any person wishing to consult the same.
Sl.
No.
Name of the
Scheduled
Formulation
Dosage form
& Strength
Unit
Ceiling
Price
(Rs.)
Review Order
number and date
Existing SO number
and date
(1)
(2)
(3)
(4)
(5)
(6)
(7)
1.
Povidone Iodine
Solution 10%
1 ml
0.87
31015/24/2018-
Pricing dated
08.10.2018
1461(E) dated
02.04.2018
(at Sl. No. 662)
4
THE GAZETTE OF INDIA : EXTRAORDINARY
[PART II—SEC. 3(ii)]
(f) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in
the above table launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing
manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified
under Schedule-II of the DPCO, 2013.
(g) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in
respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the
DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said
scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production
and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six
months prior to the intended date of discontinuation.
(h) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to
deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices
Control) Order, 2013 read with Essential Commodities Act, 1955.
(i) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above
table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above
said date of notification, stand(s) superseded.
[PN/193/61/2018/F /F. No. 8(61)/2018/D.P./NPPA-Div.-II]
BALJIT SINGH, Asstt. Director
vkns’k
ubZ fnYyh] 21 fnlEcj] 2018
dk-vk- 6253¼v½-—Hkkjr ljdkj ds jlk;u vkSj moZjd ea=ky; }kjk tkjh dk0 vk0 1394¼v½ rkjh[k
30 ebZ] 2013 vkSj dk-vk- 701¼v½ rkjh[k 10 ekpZ] 2016 ds lkFk ifBr vkS"k/k ¼dher fu;a=.k½ vkns'k] 2013 ds
iSjk 5, 11 vkSj 15 }kjk iznRr 'kfDr;ksa dk iz;ksx djrs gq,] jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k ¼ftldks
laf{kIr :i esa ,uihih, dgk tkrk gS½] uhps dh lkj.kh ds LraHk ¼6½ eas fofufnZ"V [kqnjk ewY; dks mDr lkj.kh ds
LraHk ¼3½] ¼4½] vkSj ¼5½ eas rRLFkkuh izfof"V;ksa esa fofufnZ"V izcyrk] bdkbZ ¼;wfuV½ vkSj fofuekZrk vkSj foi.ku
dEifu;ksa ds uke lfgr LraHk ¼2½ esa dh rRLFkkuh izfof"V esa ls izR;sd dh] oLrq ,oa lsok dj] ;fn dksbZ gS] dks
NksM+dj vf/kdre [kqnjk ewY; ds :i esa fu;r djrh gSA
lkj.kh
dz-
la-
vuqlwfpr fofufeZfr dk
uke@czkaM dk uke
izcyrk
bdkbZ
fofuekZrk vkSj foi.ku
daiuh
[kqnjk
ewY; ¼#-½
(1)
(2)
(3)
(4)
(5)
(6)
1.
VsyfelkVZu $
,eyksfMfiu $
gkbMªksDyksjFkkbtkbM
xksyh
¼VsyfejkbM&,,e,p½
izR;sd fQYe fyfir fcys;MZ xksyh esa%
VsyfelkVZu vkbZih 40 fexzk-]
,eyksfMfiu fclkbysV vkbZih ds cjkcj
,eyksfMfiu 5 fexzk-]
gkbMªksDyksjFkkbtkbM vkbZih 12-50 xksyh
1 xksyh
eSllZ ;wuhlu
QkekZL;wfVdYl izk- fy-
3.21
2.
VsyfelkVZu $
esVksizksyksy xksyh
¼VsyfejkbM&,eVh 25½
izR;sd vfyfir fcys;MZ xksyh esa%
VsyfelkVZu vkbZih 40 fexzk-]
esVksizksyksy lqLlkbusV vkbZih 23-75 fexzk-
ds cjkcj esVksizksyksy VkjVªsV vkbZih 25
fexzk- ¼,DlVsaMsM fjfyt esa½
1 xksyh
eSllZ ;wuhlu
QkekZL;wfVdYl izk- fy-
3.13
3.
VsyfelkVZu $
esVksizksyksy xksyh
¼VsyfejkbM&,eVh 50½
izR;sd vfyfir fcys;MZ xksyh esa%
VsyfelkVZu vkbZih 40 fexzk-]
esVksizksyksy lqLlkbusV vkbZih 47-50 fexzk-
ds cjkcj esVksizksyksy VkjVªsV vkbZih 50
fexzk- ¼,DlVsaMsM fjfyt esa½
1 xksyh
eSllZ ;wuhlu
QkekZL;wfVdYl izk- fy-
3.57
4.
vksesizktksy $
MkseisjhMksu dSIlwy
¼vksts,lvks,u&Mh½
izR;sd gkMZ tsysVkbu dSIlwy esa%
vksesizktksy 20 fexzk- ¼buVsfjd fyfir
isysVl esa½
MkseisjhMksu vkbZih 10 fexzk- ¼fyfir
isysVl esa½ dSIlwy
1 dSIlwy
eSllZ ;wuhlu
QkekZL;wfVdYl izk- fy-
1.79
¹Hkkx IIµ[k.M 3(ii)º
Hkkjr dk jkti=k % vlk/kj.k
5
5.
ysehoqMkbu $
VsuksQksohj $
MksyqxsVªohj xksyh
¼fMyVªk½
izR;sd fQYe fyfir xksyh esa%
ysehoqMkbu vkbZih 300 fexzk-]
VsuksQksohj fMlksizkDlhy QqekjsV vkbZih
300 fexzk-]
MksyqxsVªohj lksfM;e ds cjkcj MksyqxsVªohj
50 fexzk-
1 xksyh
eSllZ vkSjksfcaMks QkekZ fy-
114.06
6.
esVQksfeZu $
fi;ksXyhVktksu xksyh
izR;sd vfyfir xksyh esa%
esVQksfeZu gkbMªksDyksjkbM vkbZih 1000
fexzk- ¼lLVsaM fjfyt QkWeZ esa½]
fi;ksXyhVktksu gkbMªksDyksjkbM vkbZih ds
cjkcj fi;ksXyhVktksu 15 fexzk-
1 xksyh
eSllZ ,jhl ykbQlkbal
9.04
7.
DyhuhfMikbu $
esVksizksyksy xksyh
izR;sd fQYe fyfir fcys;MZ xksyh esa%
DyhuhfMikbu vkbZih 10 fexzk-]
esVksizksyksy lDlhusV vkbZih 23-75 fexzk-
ds cjkcj esVksizksyksy VkjVªsV 25 fexzk-
¼izksyksxsM fjfyt QkWeZ esa½
1 xksyh
eSllZ lQsVc ykbQ
lkbal@eSllZ ,tark QkekZ
fy-
6.79
8.
DyhuhfMikbu $
esVksizksyksy xksyh
izR;sd fQYe fyfir fcys;MZ xksyh esa%
DyhuhfMikbu vkbZih 10 fexzk-]
esVksizksyksy lDlhusV vkbZih 47-50 fexzk-
ds cjkcj esVksizksyksy VkjVªsV 50 fexzk-
¼izksyksxsM fjfyt QkWeZ esa½
1 xksyh
eSllZ lQsVc ykbQ
lkbal@eSllZ ,tark QkekZ
fy-
8.19
9.
jkstqokLVkfVu $
,fLifju $ DyksfiMksxzsy
dSIlwy
izR;sd gkMZ tsysVkbu dSIlwy esa%
jkstqokLVkfVu dSfY’k;e vkbZih ds cjkcj
jkstqokLVkfVu 20 fexzk- ¼isysVl esa½]
,fLifju vkbZih 75 fexzk- ¼,uVsfjd
fyfir isysVl esa½ DyksfiMksxzsy ckbZlYQsV
vkbZih ds cjkcj DyksfiMksxzsy 75 fexzk-
¼isysVl esa½
1 dSIlwy
eSllZ lk;uksdse
QkekZL;wfVdYl fy-@eSllZ
ekbØks yScl fy-
17.88
10.
jkstqokLVkfVu $
,fLifju $ DyksfiMksxzsy
dSIlwy
izR;sd gkMZ tsysVkbu dSIlwy esa%
jkstqokLVkfVu dSfY’k;e vkbZih ds cjkcj
jkstqokLVkfVu 20 fexzk- ¼isysVl esa½]
,fLifju vkbZih 75 fexzk- ¼,uVsfjd
fyfir isysVl esa½ DyksfiMksxzsy ckbZlYQsV
vkbZih ds cjkcj DyksfiMksxzsy 75 fexzk-
¼isysVl esa½
1 dSIlwy
eSllZ lk;uksdse
QkekZL;wfVdYl fy-@eSllZ
ekbØks yScl fy-
11.46
11.
blhVkyksizke $
Dyksuktsike xksyh
¼jslhVk ,yMh½
izR;sd fQYe fyfir xksyh esa%
blhVkyksizke vksDlkysV ds cjkcj
blhVkyksizke 5 fexzk-]
Dyksuktsike vkbZ 0-25 fexzk-
1 xksyh
eSllZ vkbZihlh,
yscksjsVjht fy-
5.88
12.
XyhesihjkbM $
fi;ksXyhVktksu xksyh
izR;sd vfyfir xksyh esa%
XyhesihjkbM vkbZih 1 fexzk-]
fi;ksXyhVktksu gkbMªksDyksjkbM vkbZih ds
cjkcj fi;ksXyhVktksu 15 fexzk-
1 xksyh
eSllZ foaMykl ck;ksVsd izk-
fy-@eSllZ yqfiu fy-
6.38
13.
XyhesihjkbM $
fi;ksXyhVktksu xksyh
izR;sd vfyfir xksyh esa%
XyhesihjkbM vkbZih 2 fexzk-]
fi;ksXyhVktksu gkbMªksDyksjkbM vkbZih ds
cjkcj fi;ksXyhVktksu 15 fexzk-
1 xksyh
eSllZ foaMykl ck;ksVsd izk-
fy-@eSllZ yqfiu fy-
8.20
14.
fMDyksQsud $
lsjkfV;ksiks,VhMkl
xksyh ¼fMDyksVky ,l½
izR;sd ,uVsfjd fyfir xksyh esa%
fMDyksQsud lksfM;e vkbZih 50 fexzk-]
lsjkfV;ksiks,VhMkl vkbZih 10 fexzk- ds
cjkcj 20000 ,utkbeh ,DVhohVh ;wfuVl
vkWQ lsjkfV;ksiks,VhMkl
1 xksyh
eSllZ ,dEl MªXl ,aM
QkekZL;wfVdYl fy-@eSllZ
Cyw Øksl yscksjsVjht izk-
fy-
5.00
15.
,eksDlhflYyhu $
DykoqysuV ,flM
lLisa’ku
izR;sd dkWEchiSd esa%
¼d½ ou cksVy vkWQ ,eksDlhflYyhu ,aM
iksVsf’k;e DykoqysuV vksjy lLisa’ku
vkbZih izR;sd 5 fefy- vkWQ fjdalfVVwM
lLisa’ku esa%
,eksDlhflYyhu VªhgkbMªsV vkbZih ds
cjkcj ,eksDlhflYyhu 400 fexzk-]
iksVsf’k;e DykoqysuV fMyqfVM vkbZih ds
1 fefy-
eSllZ efyd ykbQ
lkbaflt fy-@eSllZ
oksdgkMZV fy-
3.28
6
THE GAZETTE OF INDIA : EXTRAORDINARY
[PART II—SEC. 3(ii)]
cjkcj DykoqysuV ,flM 57 fexzk-]
¼[k½ ou ok;y vkWQ LVhfjy okWVj QkWj
batsD’ku vkbZih izR;sd ok;y esa%
LVhfjy okWVj QkWj batsD’ku vkbZih 30
fefy-
16.
isjkflVkeksy $
QsuhysQjhu $ dSQhu
$ fMQsugkMªkekbu
xksyh
¼useks&dksYM&,u,Q½
izR;sd vfyfir xksyh esa%
isjkflVkeksy vkbZih 500 fexzk-]
QsuhysQjhu gkbMªksDyksjkbM vkbZih 5
fexzk-]
dSQhu ¼,ugkbMªkst½ vkbZih 30 fexzk-]
fMQsugkMªkekbu gkbMªksDyksjkbM vkbZih 25
fexzk-
1 xksyh
eSllZ lselu yscksjsVjht
izk-fy-@eSllZ xYQk
yscksjsVjht fy-
2.70
17.
MsDykVklohj $
lksQkscqohj xksyh
izR;sd fQYe fyfir xksyh esa%
MsDykVklohj fMgkbMªksDyksjkbM ds cjkcj
MsDykVklohj 60 fexzk-]
lksQkscqohj 400 fexzk-
1 xksyh
eSllZ eSllZ ukVdks QkekZ
fy-@eSllZ ,izktj
gsYFkds;j izk- fy-
556.442
18.
dksyhu lSfyflysV
lksyq’ku $
csutkydksfu;e
DyksjkbM lksyq’ku $
fyXuksdsu
gkbMªksDyksjkbM tsy
¼myQzh tsy½
dksyhu lSfyflysV lksyq’ku ch-ih- ds
cjkcj dksyhu lSfyflysV 8-7%
MCY;w@MCY;w]
csutkydksfu;e DyksjkbM lksyq’ku vkbZih
0001% MCY;w@MCY;w]
fyXuksdsu gkbMªksDyksjkbM vkbZih 2-0
1 xzke
eSllZ xzqi QkekZL;wfVdYl
fy-@eSllZ gsVsjks gsYFkds;j
fy-
4.29
19.
cqfiokdkbu $ QsaVfuy
batSD’ku
izR;sd fefy- esa%
cqfiokdkbu gkbMªksDyksjkbM vkbZih 1-00
fexzk- ds cjkcj bugkbMªkst cqfiokdkbu
gkbMªksDyksjkbM 0-948 fexzk-]
QsaVfuy lkbVªsV vkbZih ds cjkcj QsaVfuy
2-0 ,elhth
20 fefy-
ok;y
eSllZ Vªksbdk
QkekZL;wfVdYl fy-
71.43
20.
cqfiokdkbu $ QsaVfuy
batSD’ku
izR;sd fefy- esa%
cqfiokdkbu gkbMªksDyksjkbM vkbZih 1-25
fexzk- ds cjkcj bugkbMªkst cqfiokdkbu
gkbMªksDyksjkbM 1-185 fexzk-]
QsaVfuy lkbVªsV vkbZih ds cjkcj QsaVfuy
2-0 ,elhth
20 fefy-
ok;y
eSllZ Vªksbdk
QkekZL;wfVdYl fy-
75.89
21.
fMIFkhfj;k VksDlkW;M $
VsVul VksDlkW;M $
fufӯ; MCY;w&ch
ijVqLlhl cYd $ fgc
¼ihvkjih&VhVh½ ¼fgc
ihvkjih dutxVhM
fon dSfj;j izksVhu
VsVul VksDlkW;M½ $
,Y;wfefu;e lkexzh ¼,
13½ ¼,Y;wfefu;e
QkWLQsV tsy ds :i esa½
fFk;ksekjly 0-025
fexzk- ¼bth Qksj½
izR;sd iSd esa%
fMIFkhfj;k VksDlkW;M 20 ,y,Q ¼30
vkbZ;w½]
VsVul VksDlkW;M 7-5 ,y,Q ¼30 vkbZ;w½]
fufӯ; MCY;w&ch ijVqLlhl cYd 10
vkbZvks;w ¼4 vkbZ;w½]
fgc ¼ihvkjih&VhVh½ ¼fgc ihvkjih
dutxVhM fon dSfj;j izksVhu VsVul
VksDlkW;M½ 10 ;wth]
,Y;wfefu;e lkexzh ¼, 13$½ ¼,Y;wfefu;e
QkWLQsV tsy ds :i esa½ 0-25 fexzk-]
fFk;ksekjly 0-025 fexzk-
0-5 fefy-
eSllZ isusfl;k ck;ksVsd fy-
340.15
22.
QkWeksZVsjksy Q~;wejsV $
cqMslksukbM bugsys’ku
lLisa’ku ¼LekVZwyl½
izR;sd 2 fefy- bugsys’ku lLisa’ku esa%
QkWeksZVsjksy Q~;wejsV fMgkbMªsV vkbZih ds
cjkcj QkWeksZVsjksy Q~;wejsV 20 ,elhth]
cqMslksukbM vkbZih 0-5 fexzk- bu ,u
blksVksfud lksyq’ku
2 fefy-
eSllZ ,dEl MªXl ,aM
QkekZL;wfVdYl fy-@eSllZ
XysuekdZ QkekZL;wfVdYl
fy-
36.04
23.
QkWeksZVsjksy Q~;wejsV $
cqMslksukbM bugsys’ku
lLisa’ku ¼LekVZwyl½
izR;sd 2 fefy- bugsys’ku lLisa’ku esa%
QkWeksZVsjksy Q~;wejsV fMgkbMªsV vkbZih ds
cjkcj QkWeksZVsjksy Q~;wejsV 20 ,elhth]
cqMslksukbM vkbZih 1 fexzk- bu ,u
blksVksfud lksyq’ku
2 fefy-
eSllZ ,dEl MªXl ,aM
QkekZL;wfVdYl fy-@eSllZ
XysuekdZ QkekZL;wfVdYl
fy-
42.12
¹Hkkx IIµ[k.M 3(ii)º
Hkkjr dk jkti=k % vlk/kj.k
7
uksV %
¼d½ mi;qZDr nh xbZ fofufnZ"V QkWewZys'ku ds fofuekZrk vFkkZr tks ÞubZ Mªxß Mhihlhvks] 2013 ds iSjkxzkQ 2¼;w½ ds
rgr mi;qZDr nh xbZ lkj.kh ds LraHk ¼6½ esa fofufnZ"V [kqnjk ewY; fu/kkZfjr djsaxsA
¼[k½ vxj fuekZrkvksa us mi;qZDr lkj.kh ds LraHk (6) esa of.kZr vf/kdre dher ij ljdkj dks okLro esa Hkqxrku
fd;k gS ;k ;g ns; gS rks os oLrq ,oa lsok dj dks tksM+ ldrs gSaA
¼x½ vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds iSjkxzkQ 11 esa fn, x, izko/kkuksa ds rgr fuekZrkvksa dks mi;qZDr
lkj.kh ds LraHk ¼6½ esa fofufnZ"V [kqnjk ewY; ds vk/kkj ij vuqlwfpr fofufeZfr;ksa ds iSdksa ds fy, [kqnjk ewY;
fu/kkZfjr djsaA fuekZrk vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds iSjkxzkQ 24 ds rgr QkWeZ V esa vf/klwpuk dh
rkjh[k ls ,d ewY; lwph ,uihih, dks vkbZihMh,e,l ds ek/;e ls tkjh djsaA
¼?k½ vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds 24 (4) ds mica/kksa ds vuqlkj izR;sd QqVdj fodzsrk vkSj forjd
fofuekZrk }kjk fn, x, :i esa ,sls ifjlj] tgka dkjckj dks bl izdkj fd;k tk jgk gS fd mlls ijke’kZ ds
bPNqd fdlh O;fDr ds fy, igqap vklku gks] ogka mlds fdlh lgtn`’; Hkkx ij dher lwph vkSj iwjd lwph]
;fn dksbZ gks] dks laiznf’kZr djsxkA
¼M-½ mi;qZDr xSj vf/kdre dher ¼[kqnjk ewY;½ dsoy mi;qZDr [email protected] ds fy, ykxw gS tSlk fd mUgksaus
vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds rgr vuqc) ewY; fu/kkZj.k@la'kks/ku ds fy, QkWeZ I ij tek fd;k x;k
Fkk vkSj ljdkj }kjk fu/kkZfjr lHkh ykxw oS/kkfud vko';drkvksa dh iwfrZ ds v/khu izklafxd fof/k;ksa@fu;eksa ds
vUrxZr tSlk fd dsUnzh;@jkT; ykblsflax vkWFkksfjVh ds l{ke izkf/kdkjh }kjk esU;wQsDpfjax ykblsal eatwjh ds
rgr lacaf/kr fofufeZr [email protected] dEifu;ka tks vuqikyu djrh gSA
¼p½ fofuekZrk ;k foi.ku dEiuh] mijksDr fofufeZfr;ksa vkSj fofufnZ"V 'krks± dk ikyu ugha djrh gSa rks os
vko';d oLrq,¡ vf/kfu;e] 1955 ds lkFk ifBr Mhihlhvks] 2013 ds izko/kkuksa ds v/khu C;kt lfgr vf/kizHkkfjr
jkf'k dks tek djus ds fy, nk;h gksaxsA
¼N½ bl vkns'k esa mijksDr lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V fofufeZfr;ksa ds iSdksa dh
[kqnjk ewY; fu;r gksus ds ifj.kkeLo#i] vkns'k tks fd bl vkns'k ls iwoZ tkjh gq, gS] Lor% gh fujLr gks
tk;saxsA
[dka- la-@193@61@2018@,Q@Qk- la- 8¼61½@2018@Mhih@,uihih,&fMoh-II]
cythr flag] lgk;d funs'kd
ORDER
New Delhi, the 21st December, 2018
S.O. 6253(E).—In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices
Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S. O. 701(E) dated 10th March,
2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National
Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in
column (6) of the table herein below as the retail price, exclusive of goods and services tax, if any, in relation
to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit
and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4)
and (5) thereof;
TABLE
Sl.
No.
Name of the
Formulation /
Brand Name
Strength
Unit
Manufacturer &
Marketing Company
Retail
Price
(Rs.)
(1)
(2)
(3)
(4)
(5)
(6)
1.
Telmisartan +
Amlodipine +
Hydrochlorthaiazide
Tablets
(Telmiride – AMH)
Each film coated bilayered tablet
contains:
Telmisartan IP 40mg,
Amlodipine Besylate IP eq. to
Amlodipine 5mg,
Hydrochlorthaiazide IP 12.50mg
Tablets
1 Tablet
M/s Unison
Pharmaceuticals Pvt.
Ltd.
3.21
8
THE GAZETTE OF INDIA : EXTRAORDINARY
[PART II—SEC. 3(ii)]
2.
Telmisartan +
Metoprolol Tablet
(Telmiride – MT 25)
Each uncoated bilayered tablet
contains:
Telmisartan IP 40mg,
Metoprolol Succinate IP 23.75mg,
eq. to Metoprolol Tartrate IP 25mg
(as Extended Release)
1 Tablet
M/s Unison
Pharmaceuticals Pvt.
Ltd.
3.13
3.
Telmisartan +
Metoprolol Tablet
(Telmiride – MT 50)
Each uncoated bilayered tablet
contains:
Telmisartan IP 40mg,
Metoprolol Succinate IP 47.50mg,
eq. to Metoprolol Tartrate IP 50mg
(as Extended Release)
1 Tablet
M/s Unison
Pharmaceuticals Pvt.
Ltd.
3.57
4.
Omeprazole +
Domperidone
Capsule (OZSON-D)
Each hard gelatin capsule contains:
Omeprazole 20mg (As enteric coated
pellets) +
Domperidone IP 10mg (As coated
pellets) Capsule
1 Capsule
M/s Unison
Pharmaceuticals Pvt.
Ltd.
1.79
5.
(Diltra Tablets)
Lamivudine +
Tenofovir +
Dolugetravir Tablets
Each film coated tablet contains:
Lamivudine IP 300mg,
Tenofovir Disoproxil Fumarate IP
300mg
Dolugetravir Sodium eq. to
Dolutegravir 50mg
1 Tablet
M/s Aurobindo Pharma
Limited
114.06
6.
Metformin +
Pioglitazone Tablet
Each uncoated tablet contains:
Metformin Hydrochloride IP
1000mg (in sustained release form),
Pioglitazone Hydrochloride IP eq. to
Pioglitazone 15mg
1 Tablet
M/s Eris Lifesciences
Ltd.
9.04
7.
Clinidipine +
Metoprolol Tablet
Each Film coated bilayered tablet
contains:
Clinidipine IP 10mg,
Metoprolol Succinate IP 23.75mg eq.
to Metoprolol tartrate 25mg (In
prolonged release form)
1 Tablet
M/s Safetab Life
Science / M/s Ajanta
Pharma Limited
6.79
8.
Clinidipine +
Metoprolol Tablet
Each Film coated bilayered tablet
contains:
Clinidipine IP 10mg,
Metoprolol Succinate IP 47.50mg eq.
to Metoprolol tartrate 50mg (In
prolonged release form)
1 Tablet
M/s Safetab Life
Science / M/s Ajanta
Pharma Limited
8.19
9.
Rosuvastatin +
Aspirin +
Clopidogrel Capsule
Each Hard Gelatine Capsule
contains:
Rosuvastatin Calcium IP eq. to
Rosuvastation 20mg (As pellets)
Aspirin IP 75mg (As enteric coated
pellets)
Clopidogrel Bisulphate IP eq. to
Clopidogrel 75mg (As pellets)
1 Capsule
M/s Synokem
Pharmaceuticals Ltd. /
M/s Micro Labs
Limited
17.88
10.
Rosuvastatin +
Aspirin +
Clopidogrel Capsule
Each Hard Gelatine Capsule
contains:
Rosuvastatin Calcium IP eq. to
Rosuvastation 10mg (As pellets)
Aspirin IP 75mg (As enteric coated
pellets)
Clopidogrel Bisulphate IP eq. to
Clopidogrel 75mg (As pellets)
1 Capsule
M/s Synokem
Pharmaceuticals Ltd. /
M/s Micro Labs
Limited
11.46
¹Hkkx IIµ[k.M 3(ii)º
Hkkjr dk jkti=k % vlk/kj.k
9
11.
Escitalopram +
Clonazepam Tablet
(Recita LD)
Each film coated tablet contains:
Escitalopram Oxalate eq. to
Escitalopram 5mg,
Clonazepam IP 0.25mg
1 Tablet
M/s IPCA Laboratories
Ltd.
5.88
12.
Glimepiride +
Pioglitazone Tablet
Each uncoated tablet contains:
Glimepiride IP 1mg
Pioglitazone Hydrochloride IP eq. to
Pioglitazone 15mg
1 Tablet
M/s Windlas Biotech
Pvt. Ltd. / M/s Lupin
Limited
6.38
13.
Glimepiride +
Pioglitazone Tablet
Each uncoated tablet contains:
Glimepiride IP 2mg
Pioglitazone Hydrochloride IP eq. to
Pioglitazone 15mg
1 Tablet
M/s Windlas Biotech
Pvt. Ltd. / M/s Lupin
Limited
8.20
14.
Diclofenac +
Serratiopeotidase
Tablets
(Diclotal S)
Each enteric coated Tablet Contains:
Diclofenac Sodium IP 50mg,
Serratiopeotidase IP 10mg eq. to
20000 enzyme activity units of
Serratiopeptidase.
1 Tablet
M/s Akums Drugs &
Pharmaceuticals Ltd. /
M/s Blue Cross
Laboratories Pvt. Ltd.
5.00
15.
Amoxycillin +
Clavulanic Acid
Suspension
Each combipack contains:
(a) One bottle of Amoxycillin &
Potassium Clavunate Oral
Suspension L.P.
Each 5ml of reconstituted suspension
contains:
Amoxycillin Trihydrate IP eq. to
Amoxycillin 400mg, Potassium
Clavulante Diluted IP eq. to
Clavulnic Acid 57mg
(b) One vial of Sterile water for
Injection IP Each vail contains:
Sterile water for injection IP 30ml
1 ml
M/s Malik Life
Sciences Ltd. / M/s
Wockhardt Limited
3.28
16.
Paracetamol +
Phenylephrine +
Caffeine +
Diphenhydramine
Tablet (NEMO-
KOLD-NF)
Each uncoated tablet contains:
Paracetamol IP 500mg,
Phenylephrine Hydrochloride IP
5mg,
Caffeine (Anhydrous) IP 30mg,
Diphenhydramine Hydrochloride IP
25mg
1 Tablet
M/s Samson
Laboratories Pvt. Ltd. /
M/s Galpha
Laboratories Limited
2.70
17.
Daclatasvir +
Sofosbuvir Tablet
Each film coated tablet contains:
Daclatasvir Dihydrochloride eq. to
Daclatasvir 60mg,
Sofosbuvir 400mg
1 Tablet
M/s Natco Pharma Ltd.
/ M/s Aprazer
Healthcare Pvt. Ltd.
556.442
18.
Choline Salicylate
Solution +
Benzalkonium
Chloride Solution +
Lignocaine
Hydrochloride Gel
(ULFREE Gel)
Choline Salicylate Solution B.P. eq.
to Choline Salicylate 8.7% w/w,
Benzalkonium Chloride Solution IP
0001% w/w,
Lignocaine Hydrochloride IP 2.0%
w/w
1 GM
M/s Group
Pharmaceuticals
Limited / M/s Hetero
Healthcare Ltd.
4.29
19.
Bupivacaine +
Fentanyl Injection
Each ml Contains:
Bupivacaine Hydrochloride IP
1.00mg eq. to anyhydrous
Bupivacaine Hydrochloride
0.948mg,
Fentanyl Citrate IP eq. to Fentanyl
2.0mcg
20 ML
Vial
M/s Troikaa
Pharmaceuticals Ltd.
71.43
10
THE GAZETTE OF INDIA : EXTRAORDINARY
[PART II—SEC. 3(ii)]
20.
Bupivacaine +
Fentanyl Injection
Each ml Contains:
Bupivacaine Hydrochloride IP
1.25mg eq. to anyhydrous
Bupivacaine Hydrochloride
1.185mg,
Fentanyl Citrate IP eq. to Fentanyl
2.0mcg
20 ML
Vial
M/s Troikaa
Pharmaceuticals Ltd.
75.89
21.
Diphtheria Toxoid +
Tetanus Toxoid +
Inactivated w-B.
pertussis bulk +
Hib (PRP- TT) (Hib
PRP Conjugated
with carrier protein
Tetanus Toxoid) +
Aluminium content
(A13+) (as
Aluminium
Phosphate Gel) +
Thiomersal 0.025mg,
(Easy Four)
Each pack contains:
Diphtheria Toxoid 20Lf (30 IU),
Tetanus Toxoid 7.5Lf (60 IU),
Inactivated w-B. pertussis bulk 10
IOU (4 IU),
Hib (PRP- TT) (Hib PRP Conjugated
with carrier protein Tetanus Toxoid)
10 ug,
Aluminium content (A13+) (as
Aluminium Phosphate Gel) 0.25mg,
Thiomersal 0.025mg,
0.5 ML
M/s Panacea Biotech
Ltd.
340.15
22.
Formoterol Fumarate
+
Budesonide
Inhalation
Suspension
(Smartules)
Each 2ml Inhalation suspension
contains:
Formoterol Fumarate Dihydrate IP
eq. to Formoterol Fumarate 20mcg,
Budesonide IP 0.5mg in an Isotonic
Solution
2 ML
M/s Akums Drugs &
Pharmaceuticals Ltd. /
M/s Glenmark
Pharmaceuticals
Limited
36.04
23.
Formoterol Fumarate
+
Budesonide
Inhalation
Suspension
(Smartules)
Each 2ml Inhalation suspension
contains:
Formoterol Fumarate Dihydrate IP
eq. to Formoterol Fumarate 20mcg,
Budesonide IP 1.0mg in an Isotonic
Solution
2 ML
M/s Akums Drugs &
Pharmaceuticals Ltd. /
M/s Glenmark
Pharmaceuticals
Limited
42.12
Note :
(a) The manufacturer of above mentioned formulations i.e. “new drug” under paragraph 2(u) of the
DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.
(b) The manufacturer may add goods and services tax only if they have paid actually or it is payable to
the Government on the retail price mentioned in column (6) of the above said table.
(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned
manufacturer in accordance with the retail price specified in column (6) of the above table as per
provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in
Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS
and submit a copy to State Drug Controller and dealers.
(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the
supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the
premises where he carries on business in a manner so as to be easily accessible to any person
wishing to consult the same.
(e) The above mentioned retail price is applicable only to the individual manufacturer / marketer as
mentioned above i.e. who have applied for the same by submitting Form-I for price fixation /
revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory
requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing
license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may
be applicable, by the concerned manufacturer/marketing companies.
¹Hkkx IIµ[k.M 3(ii)º
Hkkjr dk jkti=k % vlk/kj.k
11
(f)
In case the retail price of any of the aforesaid formulations is not complied with, as per instant price
notification and notes specified hereinabove, then the concerned manufacturer/marketing company
shall be liable to deposit the overcharged amount along with the interest thereon under the provisions
of the DPCO, 2013 read with the Essential Commodities Act, 1955.
(g) Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above
table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the
above said date of notification, stand(s) superseded.
[PN/193/61/2018/F/F. No. 8(61)/2018/D.P./NPPA-Div.-II]
BALJIT SINGH, Asstt. Director
Uploaded by Dte. of Printing at Government of India Press, Ring Road, Mayapuri, New Delhi-110064
and Published by the Controller of Publications, Delhi-110054. ALOK
KUMAR
Digitally signed by
ALOK KUMAR
Date: 2018.12.21
23:01:54 +05'30'